News and Events
Celebrating CCR Careers: Mark Gilbert, M.D.
Mark Gilbert, M.D., has been a neuro-oncologist for nearly four decades, working to find better treatments for people with rare brain and spine tumors. After nearly a decade at CCR as Chief of the Neuro-Oncology Branch, he is announcing his retirement.
Read MoreClinical trial researching therapy for RUNX1 mutations
A clinical trial led by Lea C. Cunningham, M.D., Associate Research Physician in the Immune Deficiency Cellular Therapy Program, is researching a drug for RUNX1 mutations.
Read MoreThe liver controls intestinal health through the PEDF protein
A new study reveals how the liver and gut communicate to regulate stem cell expansion in the repair of damaged intestinal tissue. The finding, from the lab of Chuan Wu, M.D., Ph.D., has important implications for a lipid-lowering drug that affects that communication.
Read MoreCelebrating CCR Careers: Howard A. Young, Ph.D.
Howard A. Young, Ph.D., spent over 40 years researching cytokine gene expression, especially interferons and how they contribute to chronic inflammation and disease. Now, he has announced his retirement.
Read MoreClinical trial researching neuroendocrine neoplasms
A clinical trial led by Jaydira Del Rivero, M.D., Associate Research Physician in the Developmental Therapeutics Branch, is researching the biology of neuroendocrine neoplasms.
Read MoreClinical trial researching therapy for neuroendocrine cancer
A clinical trial led by Jaydira Del Rivero, M.D., Associate Research Physician in the Developmental Therapeutics Branch, is researching a combination drug therapy for neuroendocrine cancer.
Read MoreAligned Blog: Access in Appalachia
For people living in rural areas, access to healthcare can be a challenge. In this latest issue of Aligned, CCR Social Media Strategist Jenna Pierson writes about the experience of those living in Appalachia as they navigate healthcare and what is being done to address disparities in access to care for rural communities.
Read MoreCelebrating CCR Careers: William G. Stetler-Stevenson, M.D., Ph.D.
For over three decades, William G. Stetler-Stevenson, M.D., Ph.D., has been a leader in the field of tissue inhibitors of metalloproteinases (TIMP) biology and extracellular matrix regulation of cancer.
Read MoreCelebrating CCR Careers: Allan M. Weissman, M.D.
Allan M. Weissman, M.D., who explored the essential underpinning of ubiquitin in cancer, announces his retirement from the NCI.
Read MoreCelebrating CCR Careers: Kathleen Kelly, Ph.D.
Kathleen Kelly, Ph.D., who pioneered new frameworks for modeling and exploring how prostate cancer cells respond to anti-cancer drugs, announces her retirement from the NCI.
Read MorePROTACtion against resistance of commonly used anti-cancer drug
Drugs known as PIM kinase inhibitors are used to treat a range of cancers, but many patients develop resistance to these medications. Recent research has led to a new class of therapeutics that target the mechanism of this resistance, resulting in increased death of cancer cells.
Read More